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Objectives: To identify predictors of success for an 8 week pulmonary rehabilitation pro-
gramme (PRP) in patients with chronic obstructive pulmonary disease (COPD).
Methods: Sixty patients were stratified in subgroups according to baseline findings: airway
obstruction (FEV1  or <50% pred), pulmonary hyperinflation (TLC > or 120% pred), BMI value
(BMI > or 25), cardiovascular (CV) comorbidity, and resting PaO2 (PaO2  or <60 mmHg).
Outcome measurements of PRP were: >54 m increase in 6 min walking test (6MWT), or
>4 points reduction in total score of S. George Respiratory Questionnaire (SGRQ). Logistic
regression analysis was used.
Results: After PRP there was a significant improvement in exercise tolerance and quality of
life, which correlated with baseline FEV1/VC, PaO2, SpO2, 6MWT and SGRQ. SGRQ significantly
decreased and 6MWT significantly increased after PRP in all subgroups, except for patients with
CV comorbidities. Both univariate and multivariate logistic regression analyses showed that
BMI> 25 and resting PaO2< 60 mmHg were independent predictors of PRP efficacy in terms
of improvement of 6MWT, but not of SGRQ scores.
Conclusions: Clinical and functional baseline findings do not predict the response to PRP in
COPD. The greater efficacy in patients with BMI> 25 or with PaO2< 60 mmHg may be due to
a greater deconditioning in overweight patients, and to a larger room for improvement in
hypoxemic patients.
ª 2009 Elsevier Ltd. All rights reserved.ento Cardio-Toracico e Vas-
taria Pisana, Via Paradisa 2,
6; fax: þ39 050 580124.
sa.toscana.it (B. Vagaggini).
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There is a considerable body of evidence that pulmonary
rehabilitation programmes (PRP) induce significant benefits
in patients with chronic obstructive pulmonary disease
(COPD), as well as in the early phase of the disease.1.
Predictors for pulmonary rehabilitation programme 1225Out-patient PRP can determine an improvement in several
outcomes, such as dyspnoea index, quality of life and
increase in exercise tolerance.1,2
Several studies have focused on identifying clinical and
functional predictors of the beneficial effects of PRP in
COPD patients. FEV1, age and arterial carbon dioxide level
appear to be irrelevant to obtaining benefits from PRP,3e5
whereas the initial degree of dyspnoea seems a discrimi-
nant factor in obtaining positive results from pulmonary
rehabilitation.6,7 Psychosocial conditions are good predic-
tors of the effect of pulmonary rehabilitation.8,9 Body mass
index (BMI) is an important independent predictor of
morbidity and mortality of COPD, in terms of under-
weight,10,11 but obesity is also a cause of respiratory
symptoms and gas exchange disturbance, although no study
has been undertaken to address the role of BMI in pre-
dicting rehabilitation efficacy. COPD patients are affected
by cardiovascular diseases more frequently than other
people,12 and COPD itself is a risk factor for cardiovascular
mortality.13,14 Cardiovascular and metabolic diseases
significantly reduce the beneficial effects of pulmonary
rehabilitation.15
The aim of this study was to determine whether simple
clinical and functional baseline parameters could be
considered as predictors of a positive effect of a PRP in
patients with stable COPD. From a large database of out-
patients with COPD who completed an 8-week PRP, we
retrospectively evaluated the baseline characteristics of
these patients and we tried to correlate these baseline
characteristics with the outcome of the PRP.
Subjects and methods
Subjects
We examined 117 patients who attended an out-patient
PRP during a period of 2 years. Among these patients, 96
had a diagnosis of COPD, and 21 had other lung diseases
which may benefit from rehabilitation. Sixty patients out
of 96 concluded the PRP. The causes of withdrawal of PRP
in these 36 patients were: lack of social facilities and
compliance to the programme, COPD exacerbations, and
hospitalization for a non-pulmonary disease (Fig. 1).117 patients
started 8 weeks PRP
96 COPD patients
21 patients with
diseases other than COPD
60 completed
36 withdrawn
(18: lack of social facility)
(14: acute exacerbation)
(4: hospitalization)
Figure 1 Trial profile indicating participant flow.All patients who completed the PRP were affected by
moderate to severe COPD, which was diagnosed according
to the current guidelines.16 All of them were ex-smokers,
and referred a score of exercise dyspnoea equal or
greater than 2 according to MRC classification. They were
observed in a stable phase of the disease, free from
exacerbations in the 4 weeks before starting the PRP, and
under regular pharmacologic therapy (inhaled long-acting
beta2-agonists and/or tiotropium in all subjects, inhaled
corticosteroids in 47 patients, and oral theophylline in 13
patients).
Before starting PRP, each patient underwent a clinical
assessment, chest X-ray, detailed pulmonary function test
(PFT), resting arterial blood gas analysis, BMI evaluation
and assessment of comorbidities. Comorbities were sub-
divided into cardiovascular (stable ischaemic heart disease,
arterial hypertension under treatment, mild arrhythmias)
and other comorbidities (orthopedic, metabolic or neuro-
logic), which however did not represent an exclusion
criterion for participation in the PRP. Eight patients were
under long-term oxygen therapy (LTOT), with a resting
oxygen flow between 1 and 2.5 L/min. The main clinical
and functional findings of the patients are reported in
Table 1. There was no significant difference at the baseline
between the 60 subjects who completed the PRP and the
remaining 36 subjects who withdrew from the PRP for
different reasons, as regards FEV1 and other clinical find-
ings, except for FRC which was significantly higher in
subjects who withdrew from the PRP (136.2 36.9% vs
118.0 29.6%, pZ 0.02).
An informed consent for the rehabilitation programme
was obtained in all patients at the beginning of the PRP. No
approval by the Internal Review Board was required, as PRP
was part of the usual current clinical practice.Pulmonary rehabilitation programme (PRP)
Out-patient PRP consisted of 8 weeks of physical
training: twice a week, the patients exercised in the
hospital gym supervised by a physiotherapist, and the
remaining days of the week they exercised at home as
prescribed. Each session lasted 1 h: 30 min of training on
a cycloergometer and 30 min of unsupported upper limb
exercise.
The target training intensity on the cycloergometer
was set at 80% of the power obtained during a cardiopul-
monary exercise test (CPET) performed before the PRP.
Some patients could not perform the CPET because they
had limitations precluding the achievement of maximal
exercise: they were trained according to the degree of
dyspnoea, which was maintained at a score of 4e5 on the
Borg scale during exercise. Patients on LTOT exercised
under oxygen administration, by increasing the oxygen
flow in order to maintain an SpO2> 90% during the
training.
Before and after PRP, we measured: (a) PFT; (b) resting
arterial blood gas; (c) exercise tolerance by CPET (in 43 out
of 60 patients) and 6 min walking test (6MWT); (d) endur-
ance times of lower and upper limbs; (e) health status,
evaluated by the St. George Respiratory Questionnaire
(SGRQ).
Table 1 Baseline characteristics (mean standard devi-
ation) of the 60 COPD patients who completed PRP.
Number 60
Age (years) 69 6.8
Gender (male/female) 52/8
BMI 26.8 3.3
FVC (% pred) 76.1 16.3
FEV1 (% pred) 49.1 17.2
RV (% pred) 132.6 43.2
FRC (% pred) 118.0 29.6
TLC (% pred) 107.8 21.3
PaO2 (mmHg) 70.8 10.4
PaCO2 (mmHg) 40.0 5.7
Comorbidities (no. of patients)
No comorbidities 27
Cardiovasculara 16
Other comorbidities 17
COPD severity (no. of patients)b
Mild 4
Moderate 18
Severe 31
Very severe 7
BMI, body mass index; FEV1, forced expiratory volume in one
second; FVC, forced vital capacity; RV, residual volume; FRC,
functional residual capacity; TLC, total lung capacity; PaO2,
oxygen arterial partial pressure; PaCO2, carbon dioxide arterial
partial pressure.
a Alone or combined with other comorbidities.
b According to GOLD classification.1
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Pulmonary function tests (PFT) and arterial blood gas
analysis
PFT were performed using MedicalGraphics equipment
(Elite series pletismography, Medicalgraphics, St Paul,
USA), according to the ATS recommendations.17
Cardio pulmonary exercise testing (CPET)
Symptom-limited incremental exercise testing was per-
formed on an electrically braked cycloergometer (Cardio-
line Medical Device, Milano, Italy) using the standard 1-min
10-W incremental cycle exercise protocol. Functional and
metabolic data were monitored at rest and during exercise
by means of a computerized system (Metasoft 2, Cortex
Biophysik, Leipzig, Germany). The protocol design was as
suggested by the ATS statement.18
Six minute walking test (6MWT)
Subjects were given standardized instructions to cover the
greatest distance possible in 6 min and verbal encourage-
ment was given. The test was performed according to the
ATS statement.19
Health status evaluation
Health status was measured by means of the St. George’s
Respiratory Questionnaire (SGRQ).20Upper and lower limb endurance time
Upper limb endurance time was evaluated by measuring the
number of repetitions of unsupported upper limb elevation
until the patient complained of fatigue. Lower limb
endurance time was evaluated by monitoring how many
minutes each patient could cycle at 80% of the maximum
power obtained during the CPET.21
Statistical analysis
The values of all functional parameters were expressed as
mean and standard deviation (M SD). A paired t-test was
used to compare parameters before and after PRP, in both
the whole group and the subgroups. The correlations among
the preepost PRP changes in exercise tolerance or in
quality of life, and the different baseline findings were
examined using the Spearman Rank correlation coefficient.
A p value lower than 0.05 was considered as significant.
To evaluate the role of baseline findings in predicting the
PRP efficacy, we subdivided the subjects into different
subgroups according to: (a) airflow obstruction severity
(FEV1 50% pred, NZ 37; FEV1< 50% pred, NZ 23); (b)
pulmonary hyperinflation (TLC 120% pred, NZ 36;
TLC> 120% pred, NZ 24); (c) BMI value (>25, NZ 44; 25,
NZ 16); (d) cardiovascular comorbidity (absent, NZ 44;
present, NZ 16); (e) resting PaO2 (60 mmHg, NZ 49;
<60 mmHg, NZ 11).
Both univariate and multiple logistic analyses were done
to evaluate the presence of independent predictors of the
efficacy of PRP, which was expressed by a significant
increase in 6MWT (more than 54 m) or by a significant
decrease in SGRQ total score (more than 4 points); these
were the only binary dependent variables included alter-
natively in the logistic regression (0, no improvement; 1,
improvement). Independent variables were binary cate-
gories of the same baseline characteristics of the patients
already mentioned as possible predictors of the PRP effi-
cacy. For each binary variable, 0 was associated with the
normal value or the better of the two categories, and 1 with
the worst category. The analysis was performed using the
statistical package SPSS.
Results
After PRP there was a significant increase in 6MWT
(417.5 107.6 m vs 473.8 108.3 m, pZ 0.0001), a signifi-
cant decrease in the degree of dyspnoea measured by the
Borg scale after the 6MWT (4.1 2.4 vs 3.4 2.1,
pZ 0.0001) and in SGRQ activity, impact and total scores
(activity: 65.4 16.3% vs 59.6 16.6%, pZ 0.003; impact:
38.4 18.2% vs 32.5 15.6%, pZ 0.003; total score:
48.9 15.0% vs 43.7 13.6, pZ 0.003). In the 44 patients
who underwent the CPET, the training induced a significant
increase in the maximal workload (74.0 22.8 vs
81.6 21.8 W, pZ 0.006), a significant reduction in specific
VO2 value at isowatt (14.1 3.8 vs 11.8 3.0 mL/min/kg,
pZ 0.05) and in heart rate at isowatt (127.7 19.0 vs
118.9 14.1 bm, pZ 0.005).
The distribution of the postepre PRP changes in the
distance covered by 6MWT and in the SGRQ total score is
reported in Figs. 2 and 3. Sixty-seven percent and 50% of
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Figure 2 Distribution of postepre rehabilitation changes in 6 min walking distance (NZ 60 patients).
Predictors for pulmonary rehabilitation programme 1227COPD patients showed a clinically significant positive effect
from PRP, corresponding to a >54 m increment in 6 min
walking distance and to a >4 points reduction in SGRQ total
score, respectively.
There was a significant correlation between some
baseline variables and the improvement in 6MWT or in SGRQ
total score (Table 2). The improvement in 6MWT was
inversely correlated with the baseline 6 min walking
distance, and similarly the improvement in SGRQ total
score was again inversely correlated with the baseline
values of SGRQ scores, suggesting that subjects with poorer
exercise capacity or quality of life had greater room for
improvement. As regards other baseline variables, an
improvement in 6MWTwas directly associated with FEV1/VC
but not with FEV1 or other functional measurements, and
inversely correlated with BMI, while an improvement in0
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Figure 3 Distribution of postepre rehabilitation changes in S. GSGRQ total score was inversely associated with the baseline
PaO2 and SpO2.
The 6MWT significantly increased and SGRQ total score
significantly decreased after PRP in all subgroups, except for
patients with cardiovascular comorbidities. Table 3 shows the
results of theunivariateanalysis, takingasdependentvariable
a significant improvement in the 6 min walking distance or in
the SRRQ total score, and as independent variables the
baseline characteristics used for the defined subgroups. The
increase in 6 minwalking distancewas significantly associated
with baseline BMI (subjects with BMI> 25 had a greater
improvement in 6MWT) and with a low PaO2 (subjects with
baseline PaO2< 60 mmHg resulted in a greater improvement
in exercise tolerance). The improvement in SGRQ total score
was not significantly associated with any of the baseline
parameters considered in the analysis.[-4,-8] [-8,-12] [-12,-16] [-16,-20] [-20,-24] [-24,-28]
eorge Respiratory Questionnaire total score (NZ 57 patients).
Table 2 Relationship between baseline variables and change in the two outcomes (increase in 6 min walking distance and
decrease in SGRQ total score) after PRP.
D 6MWT DSGRQ
BMI RhoZ 0.25, pZ 0.05 n.s.
FVC (%pred) n.s. n.s.
FEV1 (%pred) n.s. n.s.
FEV1/VC (%) RhoZ 0.34, pZ 0.018 n.s.
VC (%pred) n.s. n.s.
FRC (% pred) n.s. n.s.
VR % (pred) n.s. n.s.
TLC% (pred) n.s. n.s.
PaO2 (mmHg) n.s. RhoZ 0.27, pZ 0.05
PaCO2 (mmHg) n.s. n.s.
SpO2 (%) RhoZ0.27, pZ 0.06 RhoZ 0.34, pZ 0.017
SGRQ symptoms (%) RhoZ 0.29, pZ 0.03 n.s.
SGRQ impact (%) RhoZ 0.23, pZ 0.08 RhoZ0.51, pZ 0.0002
SGRQ activity (%) n.s. RhoZ0.32, pZ 0.01
SGRQ total (%) RhoZ 0.26, pZ 0.05 RhoZ0.47, pZ 0.001
Upper limb endurance time (min) n.s. n.s.
Lower limb endurance time (min) n.s. n.s.
6MWT (m) RhoZ0.26, pZ 0.04 n.s.
n.s., non-significant correlation.
Table 3 Odds ratio values (and confidence intervals) of
the univariate logistic regression analysis, taking as
dependent variable the increase greater than 54 m in 6 min
walking distance or the decrease greater than 4 points in
SGRQ total score, and as independent variables the pres-
ence of functional abnormalities (FEV1< 50% pred, or
TLC> 120% pred), or cardiovascular comorbidities, or
higher BMI (>25) or low PaO2 (<60 mmHg) in the baseline
evaluation.
6MWT SGRQ total score
OR IC OR IC
FEV1< 50% 0.54 0.19e1.57 0.35 0.11e1.07
TLC> 120% 0.42 0.17e2.09 0.53 0.13e2.08
CV comorbidities 0.93 0.29e2.95 0.43 0.13e1.34
BMI> 25 5.2** 1.29e20.89 0.26 0.60e6.64
PaO2< 60 mmHg 4.21* 0.99e17.87 1.10 0.29e4.12
*pZ 0.051; **pZ 0.02.
1228 B. Vagaggini et al.In the multiple logistic regression analysis, only
a BMI> 25 and a resting PaO2< 60 mmHg resulted as inde-
pendent predictors for the efficacy of the PRP when an
increase of 54 m in 6MWT was considered (Table 4). These
relationships continued to be significant when baseline
6MWT values were included as covariates in the multi-
nominal analysis.
Discussion
In the present study, we carried out a post-hoc analysis to
examine the role of lung function, BMI and comorbidities as
predictors of the benefit of 8 weeks out-patient PRP in 60
moderateesevere COPD patients. PRP determined a signifi-
cant improvement in exercise tolerance and in health
status. BMI and PaO2 values were independent predictors of
benefit, in terms that overweight patients and those with
PaO2< 60 mmHg improved exercise tolerance more than
other subgroups.
The identification of predictive factors for pulmonary
rehabilitation have been investigated in several studies.4e10
We considered the severity of the disease according to the
FEV1 value as suggested by the international guidelines.
15 In
our study, FEV1 was not a predictor of the efficacy of PRP,
while the FEV1/VC ratio correlated with the improvement
obtained after PRP, showing that patients with less severe
airway obstruction gained greater improvement in 6 min
walking distance. We did not find any significant difference,
in terms of the results obtained from the PRP, between
subgroups of patients in TLC; this observation does not
support the hypothesis that hyperinflation can represent
a limit for the benefit from PRP.22
Gas exchange is an important marker of severity of
COPD, and may represent a limitation to the physical
activity in more severe patients. Chronic hypoxicrespiratory failure may cause relevant changes in skeletal
muscles23 but it is not an exclusion criterion for pulmonary
rehabilitation, or for patients with associated hyper-
capnia.5 In our study, subjects with a resting
PaO2< 60 mmHg obtained a greater improvement in 6 min
walking distance than non-hypoxemic patients. This could
be due to the larger room for improvement that these
patients may have from a PRP: they are often more home-
bound, have greater limitation to exercise, and suffer from
greater dyspnoea. Our hypoxemic patients were not
significantly different from non-hypoxemic patients in
terms of other markers of the disease (pulmonary function,
exercise tolerance and quality of life), and PaO2 also
Table 4 Odds ratio values (and confidence intervals) of
the multiple logistic regression analysis, taking as depen-
dent variable the increase greater than 54 m in 6 min
walking distance or the decrease greater than 4 points in
SGRQ total score, and as independent variables the pres-
ence of functional abnormalities (FEV1< 50% pred, or
TLC> 120% pred), or cardiovascular comorbidities, or
higher BMI (>25) or low PaO2 (<60 mmHg) in the baseline
evaluation.
6MWT SGRQ total score
OR IC OR IC
FEV1< 50% 0.31 0.07e1.30 0.45 0.12e1.75
TLC> 120% 1.86 0.32e10.71 2.07 0.38e11.20
CV comorbidities 2.28 0.49e10.23 0.46 0.11e1.85
BMI> 25 12.80* 1.77e91.92 3.23 0.72e14.50
PaO2< 60 mmHg 11.21* 1.33e95.04 0.86 0.14e5.18
*pZ 0.02.
Predictors for pulmonary rehabilitation programme 1229remained a significant determinant of the efficacy of the
PRP in the multiple logistic analysis, suggesting that in
effect these patients are sensitive to the positive effect of
the pulmonary rehabilitation. Furthermore, hypoxemic
patients exercised under oxygen administration and were
encouraged to perform exercise at home under oxygen
therapy.
BMI could be a determinant of PRP efficacy. A BMI value
below 19 is associated with an increased risk of death in
COPD.10,11 In our group, just four patients had a BMI lower
than 19, so the prognostic factor of being underweight
could not be evaluated in our study. On the other hand, we
found that an initial BMI> 25 was correlated with more
significant benefits from the PRP. A possible explanation for
this result could be that overweight patients may be more
deconditioned, and so they may benefit more from a pro-
gramme aiming to improve physical activity. BMI also
remained a significant determinant of the efficacy of the
PRP in the multiple logistic analysis, suggesting that over-
weight patients are sensitive to the positive effect of
pulmonary rehabilitation. Unfortunately, we did not
systematically check body weight at the and of the PRP, so
we can not attribute this positive effect to a reduction in
BMI. In the limited number of patients where this measure
was available, no significant reduction in body weight was
observed. Because at the time of the present study we
were also unable to measure fat-free mass before and after
PRP, we can not assess any redistribution of weight
between fat-free and fat mass following PRP.
The presence of comorbidities, in particular cardiovas-
cular diseases, can be a possible predictor of the outcome
of the PRP, because it is well known that these diseases are
often associated with COPD. In the Lung Health Study,
cardiovascular diseases accounted for 42% of first hospi-
talizations and for 44% of second hospitalizations of
patients with relatively mild COPD,24 and strong epidemi-
ological evidence points to reduced FEV1 as a marker for
cardiovascular mortality.13 Despite this strong association,
the presence of cardiovascular comorbidities in COPD
patients as predictors of benefits for PRP has scarcely been
examined. A recent study, performed on a large number ofpatients with COPD who underwent an intensive PRP mainly
as in-patients, has shown that the improvement in 6MWT,
exercise dyspnoea and SGRQ scores was significantly
greater in patients without significant comorbidities and
was inversely related to the Charlson Index.15 Our study has
taken into account only the influence of cardiovascular
comorbidities on the PRP results: these do not represent an
exclusion criterion from a PRP if they are well controlled by
the pharmacologic therapy. All patients participating in our
PRP at the start of the programme referred stable cardio-
vascular situations under regular treatment. COPD patients
with CV comorbidities did not show significant improvement
in 6MWT or SGRQ total score, but this could be related to
the limited number of these subjects. Considering that
COPD is a systemic disease, it could be of interest in the
future to examine the influence of other comorbidities, as
such as diabetes or osteoporosis, in larger groups of COPD
patients.
While in the univariate and multivariate logistic analysis
the improvement in 6MWT was partially determined by
some baseline findings, no predictors of the improvement
of SGRQ total score was observed. Although scores obtained
by SGRQ have been used as a good marker of the health-
related quality of life in COPD patients, they are influenced
by several different aspects of the disease, including
psychological and social factors, and this can reduce the
possibility of seeing any association with specific physio-
logic findings.
A major point of discussion is whether the results we
obtained suggest real pathophysiologic differences in the
response to pulmonary rehabilitation in subjects with
higher BMI or lower PaO2.
Obesity is associated with relevant changes in pulmonary
mechanics and gas exchanges alterations,25 but how these
abnormalities may influence the results of a PRP is not
known.1 A recent paper shows a similar improvement
following PRP in obese and non-obese patients.26 Although
our patients were only overweight, we may suppose that
the exercise training was able to improve pulmonary
ventilation and reduce dyspnoea perception, resulting in
better exercise performance.
Few papers have demonstrated that hypoxemic
patients, or non-hypoxemic patients who developed desa-
turation during exercise, obtained some benefits from
exercise training under oxygen supplementation,1,27,28
although no direct comparison between hypoxemic and
non-hypoxemic patients has been reported in term of effi-
cacy of a PRP. Hypoxemia causes a low anaerobic threshold
during exercise, which determines an early increase of
respiratory frequency, with a consequent increase in
dynamic hyperinflation and early interruption of exercise.29
Adequate oxygen supplementation during exercise
increases oxygen delivery to skeletal muscles which delays
the anaerobic threshold and reduces the work of breathing.
Therefore we may suppose that hypoxemic patients
improve their exercise tolerance more than non-hypoxemic
patients after a PRP, at least in comparison with their
baseline values.
In addition to these pathophysiologic explanations of our
results, we believe that the greater efficacy that these
subgroups of patients may have from a PRP is mainly due to
the lower level of physical activity they were performing
1230 B. Vagaggini et al.before the beginning of the PRP, for different reasons
(overweight or limitation in daily life due to LTOT). These
patients may have more room for improvement, particu-
larly as regards exercise tolerance. However, this obser-
vation supports the recommendation to not exclude
patients with low exercise capacity from a PRP.
In conclusion, this study does not support the hypothesis
that simple clinical and functional baseline findings may
predict the response to a PRP in moderate-to-severe COPD
patients. The greater improvement in 6MWT showed by
patients with BMI> 25 and by patients with
PaO2< 60 mmHg may be due to a greater deconditioning in
overweight patients, and to more room for improvement in
hypoxemic patients. These data support the hypothesis
that a poorer baseline condition can leave greater possi-
bility for improvement in patients with moderate-to-severe
COPD but who are still able to attend an out-patient PRP.
The same considerations are not applicable in more severe
COPD patients. Finally, these data support the current
recommendations on the usefulness of pulmonary rehabil-
itation in most subgroups of COPD patients.
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